Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report report published on Monday morning,Benzinga reports. They currently have a $19.00 price target on the stock.

TRVI has been the topic of several other reports. Oppenheimer increased their target price on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Stifel Nicolaus boosted their price target on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. B. Riley Financial raised Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Finally, Morgan Stanley lifted their target price on Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI opened at $11.94 on Monday. The firm’s 50 day simple moving average is $11.21 and its 200 day simple moving average is $10.80. Trevi Therapeutics has a fifty-two week low of $4.85 and a fifty-two week high of $14.39. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -32.27 and a beta of 0.94.

Institutional Investors Weigh In On Trevi Therapeutics

Several large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of Trevi Therapeutics by 4.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock worth $195,000 after acquiring an additional 911 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock worth $70,000 after purchasing an additional 1,300 shares during the period. Kennedy Capital Management LLC increased its holdings in Trevi Therapeutics by 2.4% during the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock worth $704,000 after purchasing an additional 1,336 shares in the last quarter. Persistent Asset Partners Ltd increased its holdings in Trevi Therapeutics by 3.3% during the 2nd quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company’s stock worth $234,000 after purchasing an additional 1,384 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Trevi Therapeutics by 32.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares during the period. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.